w*****n
发帖数: 368 | 1 Dominique Bertrand, 法国公共卫生委员会主席，法国医学科学院院士，这么个大人物
，除了中国媒体，google结果为零。哈哈哈哈
--------------------------------------------------------------
http://www.stdaily.com/English/ChinaNews/2021-08/13/content_1212889.shtml
No need to repeat investigation on WHO first phase of origin tracing: French
expert
Source: Science and Technology Daily| 2021-08-13 08:55:44| Author: WANG
Xiaoxia
(PHOTO: CFP)
By WANG Xiaoxia
Future COVID-19 origin tracing studies need to take into account the results
of the first phase of the WHO origin tracing research, and should not
repeatedly investigate into the first phase results in the short term, said
a French scientist during a recent interview with Science and Technology
Daily.
Dominique Bertrand, President of the French National Commission of Public
Health, said that the report of WHO's first phase origin tracing should be
fully respected, and repeated origin tracing within a short period of time
should not be performed since the first report contained sufficient
objective facts.
Future origin tracing studies should be carried out on the basis of the
first-phase results. The origin tracing work conducted by experts from
multiple countries under the leadership of the WHO would contribute to the
global fight against COVID-19 pandemic, said Bertrand.
The origin of the novel coronavirus is still unknown, and there could be a
natural host, Bertrand stressed, that all countries and regions should
conduct examination of storable samples, complete the retrospective
detection and genomic sequencing of the virus, and then share the results.
Besides, countries need to pay continuous attention to the evolution of the
epidemic in various regions, especially to strengthen the detection of the
mutation of the novel coronavirus, and to track the spread of the COVID-19
variants and clinical results timely, Bertrand added.
A fourth wave of the COVID-19 pandemic has hit France, due to a resurgence
of cases caused by the Delta variant, according to Bertrand, and China's
performance in epidemic prevention was outstanding, so France attached great
importance to learning from China's experience.
Chen Xin, member of the French National Commission of Public Health, said
that countries should focus on the prevention and control of the pandemic,
and work together to avoid putting squeeze on global medical resources.
Scientists should continue to proactively pay attention to the long-term
effectiveness of vaccines and the calculation of immune protection.
Governments of all countries should focus on the vaccination rate, the
recovery of society and economy, and put forward the international exchanges
and cooperation among various industries, Chen explained.
As the Olympic motto was updated to "Faster, Higher, Stronger -
Together", solidarity across the world was urged at the time of the global
pandemic of COVID-19, said Chen. | w*****n
发帖数: 368 | 2 法国专家表示：不应重复调查世卫第一阶段溯源结论
科技日报 发布时间：2021年08月16日 09:55
法国专家表示：不应重复调查世卫第一阶段溯源结论
国际战“疫”行动
◎本报驻法国记者 李宏策
如何看待新冠病毒的来源？随着新冠病毒变异株的蔓延，未来应如何应对一波又一
波的疫情？科技日报记者就此采访了法国国家公共卫生委员会主席、法国国家医学科学
院通讯院士多米尼克·伯特兰和法国国家公共卫生委员会公共卫生主管陈新。
短期内不应对世卫第一阶段溯源结论重复调查
随着多国科学家对新冠病毒溯源的持续研究，已经有多项研究结果表明，新冠病毒
在2019年下半年已经在全球多地出现。特别是近日，在美国白尾鹿2019年的样本中检测
到新冠病毒抗体，这是首次在野生动物中发现新冠中和抗体，也是首次在野生动物中发
现早于人类的新冠病毒感染。这一新发现明确指向了世卫组织第一阶段溯源调查结果：
新冠病毒从自然宿主通过中间宿主再过渡到人是多个路径中可能性最高的。
对此，伯特兰表示，新冠病毒的起源目前仍是未知，病毒可能存在天然宿主。未来
的溯源研究需重视世卫组织第一阶段的调查结果。由多国专家组成的团队和世卫组织的
联合溯源调查将有利于抗击新冠疫情。另外，围绕溯源的努力需要所有国家的共同参与
，需要各方及时分享信息。
伯特兰强调，现阶段，已有报道显示多国出现回溯性标本检测呈阳性的实例，世界
各国及地区应从科学角度进行逻辑性可存样本的自查，厘清各国可存样本回溯病毒检测
及序列，继而加以互通分享。对于下阶段的调查，应充分尊重世卫组织的第一份溯源报
告结果，在第一份报告拥有充分客观事实前提下不应进行短时期内重复溯源。
另外，伯特兰认为，未来各国还需要对新冠病毒的可追溯性给予持续关注，包括各
地区新冠感染者的流行演变，特别是对新冠病毒的变异加强检测，及时掌握变异病毒的
传播程度和临床结果。
陈新表示，当前世界各国及地区新冠病毒变异株盛行，感染处于波峰阶段。各国应
将主要注意力置于应对现阶段的疫情防控，合力避免再次发生全球医疗资源兑挤。各国
科学家应持续积极关注疫苗长期有效率及防护免疫屏障的测算。各国政府应该将注意力
置于民众疫苗接种率、社会经济的节奏性复苏及各行业坦诚有效的国际交流合作。
采取预防策略并扩大疫苗接种
伯特兰表示，由于德尔塔变异株的流行，法国本土及海外省正遭受第四轮新冠疫情
。法国海外省的疫情尤为严重，当地疫苗接种完成率不足18%。法国本土的疫苗接种完
成率已经超过50%，一针接种率已接近70%，但仍无法阻止变异株的继续流行。
伯特兰称，德尔塔变异株具有更强的感染能力，只有采取预防策略才能够有效控制
疫情。预防新冠疫情一方面要通过各类限制措施以保持社交距离，包括对感染者和密切
接触者的科学有效隔离，加强个人防护，限制人数，以及法国刚刚通过法律并开始施行
的“健康通行证”等；另一面则需要扩大疫苗接种，因为疫苗不仅可以对个人提供保护
，还可以在达到一定接种率后形成“群体保护”。
应对新一轮疫情需借鉴中国经验
伯特兰认为，中国在防疫方面的表现最为突出，法国非常重视中国的经验。但遗憾
的是，作为疫苗之父巴斯德的诞生地，法国目前出现一部分民众以个人自由为由反对疫
苗接种和“健康通行证”措施。
对此，伯特兰强调，民众必须认识到抗击疫情需要所有人的共同努力，每个人都应
该将社会抗疫的总体目标视为个人目标，因为本质上人具有社会性，履行抗疫措施是一
种义务。
陈新表示，在刚刚结束的东京奥运会闭幕式上，作为2024年夏季奥运会的东道主，
法国总统马克龙在埃菲尔铁塔带领年轻人高喊新的奥林匹克口号：更快，更高，更强，
更团结。
更加团结，也应是人类抗击新冠疫情的宗旨。 | w*****n
发帖数: 368 | 3 主动造假，这比瑞士专家Wilson Edwards要恶劣得多。 | t******e
发帖数: 2504 | | a*****s
发帖数: 1 | | j***6
发帖数: 107 | 6 开玩笑吧？你说这个人不存在？
你真的用谷歌查了？他有不少论文的 | n***j
发帖数: 1747 | 7 下载一下PDF，有作者简介
Dominique Bertrand is Professor, Department of Public Health,
Fernand-Vidal Hospital, Assistance Publique – Hoˆ pitaux de Paris,
Paris, France.
http://www.researchgate.net/publication/8410467_Accreditation_a_Tool_for_
Organizational_Change_in_Hospitals | b******2
发帖数: 1 | 8 你会用google吗？你他妈的廊五吧？
Dominique Bertrand, MD, of Rouen University Hospital in Rouen, France, and
colleagues studied the first 45 kidney transplant recipients (mean age 63.5
years) and 10 patients on hemodialysis (mean age 71.2 years) in a cohort to
receive 2 injections of the Pfizer-BioNTech COVID-19 mRNA (BNT162b2) vaccine.
At 1 month after the second dose, anti-spike SARS-CoV-2 antibodies developed
in 8 patients on hemodialysis (88.9%) and 8 kidney transplant recipients (
17.8%), the investigators reported. The median antibody titer in responders
was 1052 AU/mL in patients on dialysis and 671 AU/mL in kidney transplant
recipients.
After the second vaccine dose, a specific T cell response was detected in 9
patients (90%) on hemodialysis (1 patient contracted COVID-19 and was
excluded) and 26 (57.8%) kidney transplant recipients. In responders, the
median number of spike-reactive T cells were 305 spot-forming cells (SFC)
per 106 CD3+ T cells in patients on hemodialysis and 212 SFC/106 CD3+ T
cells in kidney transplant recipients.
The immune response in kidney transplant recipients appeared to vary by
immunosuppressive regimen. Patients receiving belatacept had no antibody
response and no or few specific T cells, Dr Bertrand’s team reported.
Tacrolimus-treated patients generally had a weak response, except for a few
patients who mounted a T cell response. Most of the kidney transplant group
received mycophenolate mofetil, which may have influenced antibody responses.
According to Dr Bertrand’s team, the Pfizer-BioNTech COVID-19 mRNA vaccine
“seems efficient” in patients on hemodialysis, supporting vaccination of
these patients. By contrast, the low seroconversion rate observed in kidney
transplant recipients is “worrying.”
https://www.renalandurologynews.com/home/news/nephrology/transplantation/
sars-cov-2-antibody-t-cell-response-to-covid-19-mrna-vaccine-in-kidney-
transplant-dialysis/ | b******2
发帖数: 1 | 9 另一个
https://medicalxpress.com/news/2021-06-hemodialysis-patients-antibody-
response-covid-.html
Dominique Bertrand, M.D., from Rouen University Hospital in France, and
colleagues explored postvaccinal humoral and cellular response in 45 KTRs
and 10 HDPs who received two injections of mRNA BNT162b2 vaccine between Jan
. 18 and Feb. 24, 2021.
The researchers found that 88.9 percent of HDPs and 17.8 percent of KTRs
developed anti-spike SARS-CoV-2 antibodies after the second dose. In
responders, the median titers of antibodies were 1,052 and 671 AU/mL in HDPs
and KTRs, respectively. Overall, 100 and 57.8 percent of HDPs and KTRs,
respectively, showed a specific T-cell response after the second vaccination
. The median numbers of spike-reactive T cells were 305 and 212 spot-forming
cells per 106 CD3+ T cells in HDPs and KTRs, respectively. The immune
response to BNT162b2 seemed to be influenced by the immunosuppressive
regimen in KTRs, especially tacrolimus or belatacept.
"The vaccine seems efficient in individuals undergoing dialysis, indicating
that vaccination should be highly recommended in these patients," Bertrand
said in a statement. "By contrast, the low antibody response observed in
kidney transplant recipients is worrying; however, antibodies are not the
full spectrum of protection induced by the vaccine. T cell immunity is
probably also very important." | s*********2
发帖数: 1572 | 10 廊庑老将又暴漏了？
5
to
vaccine.
developed
responders
【在 b******2 的大作中提到】
: 你会用google吗？你他妈的廊五吧？
: Dominique Bertrand, MD, of Rouen University Hospital in Rouen, France, and
: colleagues studied the first 45 kidney transplant recipients (mean age 63.5
: years) and 10 patients on hemodialysis (mean age 71.2 years) in a cohort to
: receive 2 injections of the Pfizer-BioNTech COVID-19 mRNA (BNT162b2) vaccine.
: At 1 month after the second dose, anti-spike SARS-CoV-2 antibodies developed
: in 8 patients on hemodialysis (88.9%) and 8 kidney transplant recipients (
: 17.8%), the investigators reported. The median antibody titer in responders
: was 1052 AU/mL in patients on dialysis and 671 AU/mL in kidney transplant
: recipients.
| b******2
发帖数: 1 | 11 wenlian (wang)这个翻墙廊五老将，你知道咋用google吗？
发信人: wenlian (wang), 信区: Military
标 题: 天朝的科技日报制造出了一个法国专家Dominique Bertrand
发信站: BBS 未名空间站 (Mon Aug 16 16:01:41 2021, 美东)
Dominique Bertrand, 法国公共卫生委员会主席，法国医学科学院院士，这么个大人物
，除了中国媒体，google结果为零。哈哈哈哈
【在 s*********2 的大作中提到】
: 廊庑老将又暴漏了？
:
: 5
: to
: vaccine.
: developed
: responders
| m*****u
发帖数: 15526 | | c*******e
发帖数: 5818 | | b*w
发帖数: 14917 | 14 文中的陈新，就是那个上海健康医学院的常务副院长吧？ | b*w
发帖数: 14917 | 15 是学院下面健康与公共卫生学院副院长，曾经的法国专家的博士生，看简历，已经回国
2年多了。
: 文中的陈新，就是那个上海健康医学院的常务副院长吧？
【在 b*w 的大作中提到】
: 文中的陈新，就是那个上海健康医学院的常务副院长吧？
| b*w
发帖数: 14917 | 16 挺能扯虎皮吓唬人的。。。。。。。。
: 是学院下面健康与公共卫生学院副院长，曾经的法国专家的博士生，看简历，已
经回国
: 2年多了。
【在 b*w 的大作中提到】
: 是学院下面健康与公共卫生学院副院长，曾经的法国专家的博士生，看简历，已经回国
: 2年多了。
:
:
: 文中的陈新，就是那个上海健康医学院的常务副院长吧？
:
| r*****2
发帖数: 2682 | 17 这是一个pdf文件，是法语的，土包子老逼将自己看看
https://paris.notaires.fr/sites/default/files/15_juin_2015_livre_des_resumes
_colloque_dignite_humaine-06-29.pdf
法语原文
Membres : Dominique BERTRAND, Président de la Commission Nationale de la
Santé
Publique, Conseiller médical auprès de la Directrice Générale du Centre
National de Gestion;
英文翻译
Members: Dominique BERTRAND, President of the National Health Commission
Public, Medical Advisor to the General Director of the National Management
Center; |
|
